Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance-Reference-Cited by-同舟云学术

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance

Published:2014-07-21 Issue:2 Volume:78 Page:329-342
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Benz-de Bretagne Isabelle¹²,Zahr Noël³,Le Gouge Amélie⁴⁵,Hulot Jean-Sébastien³⁶,Houillier Caroline⁷,Hoang-Xuan Khe⁷,Gyan Emmanuel⁸,Lissandre Séverine⁸,Choquet Sylvain⁹,Le Guellec Chantal¹²

Affiliation:

1. Laboratoire de Biochimie et Biologie Moléculaire; CHRU de Tours; Tours France

2. Université François Rabelais de Tours; PRES Centre Val de Loire Université; EA4245 Tours France

3. Service de Pharmacologie; CHU Pitié-Salpêtrière; AP-HP Paris France

4. CHRU de Tours; Centre d'investigation clinique; Tours France

5. Université François Rabelais de Tours; PRES Centre Val de Loire Université; Inserm 202 Tours France

6. UPMC Université Paris 06; UMR_S 956 Paris France

7. Service de Neurologie; CHU Pitié-Salpêtrière; Centre expert national LOC; AP-HP Paris France

8. Service d'Hématologie et Thérapie Cellulaire; CHRU de Tours; Tours France

9. Service d'Hématologie; CHU Pitié-Salpêtrière; AP-HP Paris France

Funder

Assistance Publique - Hï¿½pitaux de Paris

National PHRC 2007

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12326/fullpdf

Reference75 articles.

1. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy;Faltaos;Cancer Chemother Pharmacol,2006

2. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data;Fukuhara;J Clin Pharm Ther,2008

3. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate;Joerger;Br J Clin Pharmacol,2011

4. Biliary elimination of low-dose methotrexate in humans;Nuernberg;Arthritis Rheum,1990

5. Clinical pharmacokinetics of methotrexate;Shen;Clin Pharmacokinet,1978

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review;European Journal of Clinical Pharmacology;2023-11-07

2. External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients;European Journal of Pharmaceutical Sciences;2023-07

3. Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma;Frontiers in Pharmacology;2022-03-09

4. Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III;Journal of Pharmacology and Experimental Therapeutics;2020-10-30

5. Body Surface Area Dosing of High-Dose Methotrexate Should be Reconsidered, Particularly in Overweight, Adult Patients;Therapeutic Drug Monitoring;2020-09-10